Overview
Shai Marshall is an associate in the Corporate practice of Paul Hastings and is based in the firm’s New York office.
Ms. Marshall’s practice primarily focuses on securities and capital markets. She represents public and private companies and financial institutions in a range of corporate matters, including public and private offerings of equity and debt securities, governance and compliance and periodic reporting requirements.
Ms. Marshall received her law degree from Fordham University School of Law in 2016, where she served as Business Editor of the Fordham Urban Law Journal. She earned a Bachelor of Arts degree in Psychology from Lehigh University in 2013. Ms. Marshall is admitted to practice law in New York.
Representations
- Citigroup, BofA Securities, BMO Capital Markets, J.P. Morgan, RBC Capital Markets and other underwriters in numerous offerings of common stock, preferred stock and senior notes by Sun Communities, Inc. (NYSE: SUI) and its operating partnership, Sun Communities Operating Limited Partnership, including:
- the joint book-running managers for Sun Communities Operating Limited Partnership’s public offerings of $1.2 billion aggregate principal amount of senior notes;
- the joint book-running managers for Sun Communities, Inc.’s $1.28 billion public offering of common stock in connection with forward sale agreements and $2.1 billion acquisition of Safe Harbor Marinas, LLC, the largest owner and operator of marinas in the United States; the joint book-running managers for Sun Communities, Inc.’s $1.13 billion public offering of common stock including $567 million of shares sold on a forward basis; and
- the sales agents for Sun Communities, Inc.’s $1.25 billion "at-the-market" (ATM) offering program.
- Citigroup, BofA Securities, Barclays, J.P. Morgan, Morgan Stanley, Wells Fargo Securities, and other underwriters in numerous offerings of class A common stock, convertible senior notes and senior secured notes by Blackstone Mortgage Trust, Inc. (NYSE: BXMT), including:
- the joint book-running managers for Blackstone Mortgage Trust, Inc.’s $300 million public offering of convertible senior notes;
- the sales agents for Blackstone Mortgage Trust, Inc.’s $500 million "at-the-market" (ATM) offering program;
- the sole book-running manager for Blackstone Mortgage Trust, Inc.’s $115 million public offering of convertible senior notes pursuant to a reopening of its existing series of such convertible senior notes; and
- the joint book-running managers for several of Blackstone Mortgage Trust, Inc.’s public offerings of its class A common stock.
- Orchestra BioMed, Inc., a biomedical innovation company, in connection with its business combination agreement to merge with a special purpose acquisition company (SPAC).
- Cresco Labs Inc. in connection with its definitive arrangement agreement to acquire Columbia Care Inc. for approximately $2 billion.
- Goldman Sachs, Morgan Stanley and BofA Securities, as joint book-running managers for Accolade, Inc.’s (Nasdaq: ACCD) initial public offering.
- The initial purchasers for Accolade, Inc.’s private offering of $250 million of convertible senior notes.
- J.P. Morgan, Goldman Sachs, Credit Suisse and Jefferies, as initial purchasers for Beyond Meat, Inc.’s (Nasdaq: BYND) private offering of $1 billion of convertible senior notes.
- Mitek Systems, Inc. (Nasdaq: MITK), a global leader in digital identity verification solutions, in its private offering of $135 million of convertible senior notes.
- Canopy Growth Corporation (Nasdaq: CGC) in connection with its:
- agreement providing Canopy with the right, upon federal permissibility of THC in the United States or earlier at Canopy’s election, to acquire up to 100% of the outstanding capital stock of Jetty, a producer of cannabis extracts and pioneer of clean vape technology;
- acquisition of The Supreme Cannabis Company, Inc. in a transaction valued at approximately $435 million on a fully-diluted basis; and
- agreement to acquire Acreage Holdings, Inc. in a transaction valued at approximately $3.4 billion.
- GE Medical Systems Information Technologies, Inc., a wholly owned subsidiary of General Electric Company, in an underwritten secondary public offering of 10,835,145 shares of common stock of NeoGenomics, Inc. (Nasdaq: NEO), a leading provider of cancer-focused genetic testing services, raising gross proceeds of approximately $130 million.
- Jefferies, as sales agent for Regis Corp.’s $50 million “at-the-market” (ATM) offering program and Revlon, Inc.’s $25 million “at-the-market” (ATM) offering program.
- A real estate private equity fund in connection with its bond offering on the Tel Aviv Stock Exchange raising gross proceeds of approximately $290 million.
- Flexential Corp., a leading provider of data center colocation and hybrid IT solutions and a portfolio company of GI Partners, in its private offering of $250 million of senior secured notes.
- Numerous initial public offerings by special purpose acquisition companies (SPACs), including Pine Island Acquisition Corp., Itiquira Acquisition Corp. and PMV Consumer Acquisition Corp.
- The underwriters on a number of initial public offerings for special purpose acquisition companies (SPACs), including Healthcor Catalio Acquisition Corp., Senior Connect Acquisition Corp. I, GO Acquisition Corp., Lux Health Tech Acquisition Corp. and Global Partner Acquisition Corp II.
- Energy Focus, Inc. (Nasdaq: EFOI), a leader in advanced LED lighting technologies and solutions, in connection with its registered direct offering of shares of common stock and concurrent private placement of warrants.
- Trinidad Petroleum Holdings Limited (TPHL), an integrated national oil and gas company owned by the Government of Trinidad and Tobago and key to the economic health of Trinidad and Tobago, in its issuer-led exchange offer for approximately US$570 million of new Senior Secured Notes due 2026, which was part of a refinancing transaction of approximately US$900 million of outstanding notes that also included a US$603 million, dual-tranche term loan facility.
- Caladrius Biosciences, Inc. (Nasdaq: CLBS), a clinical stage development company with a cell therapy pipeline focused on immune modulation and select cardiovascular indications, in the sale of its subsidiary PCT to Hitachi Chemical Co. America, Ltd.